Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVRA8N)

Drug Name

Org-2766 Drug Info

Synonyms

Org-2766; H-Met(O2)-Glu-His-Phe-D-Lys-Phe-OH; UNII-OP1H5I4TBQ; OP1H5I4TBQ; 50913-82-1; AC1OCEIT; (4S)-5-[[(2S)-1-[[(2S)-1-[[(2R)-6-amino-1-[[(2S)-1-hydroxy-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-amino-4-methylsulfonylbutanoyl]amino]-5-oxopentanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Cognitive impairment	6D71	Discontinued in Phase 3	[1]

Cross-matching ID

PubChem CID: 6917685
CAS Number: CAS 50913-82-1
TTD Drug ID: DMVRA8N

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Low-affinity nerve growth factor receptor (NGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cenegermin	DM8Y2RU	Neurotrophic keratitis	9A74	Approved	[3]
Fulranumab	DMK38MV	Arthralgia	ME82	Phase 3	[4]
SPI-205	DMHC2AW	Parkinson disease	8A00.0	Phase 2	[5]
LM11A-31	DM095HQ	Alzheimer disease	8A20	Phase 1/2	[6]
LM11A-31	DM095HQ	Alzheimer disease	8A20	Phase 1/2	[7]
BU-4514N	DMJDMTK	Alzheimer disease	8A20	Terminated	[8]
ReN-1820	DMWIAUK	Cystitis	GC00	Terminated	[9]
CEP-427	DMTI10C	Alzheimer disease	8A20	Terminated	[4]
TDI-0059	DMSI9QM	Motor neurone disease	8B60	Investigative	[4]
Nerve growth factor conjugated RAP peptide	DM3AW8X	Neurodegenerative disorder	8A20-8A23	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Low-affinity nerve growth factor receptor (NGFR)	TTEDJN4	TNR16_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000019)
2	Effects of the ACTH4-9 analog Org2766 on brain plasticity: modulation of excitatory neurotransmission. Psychoneuroendocrinology. 1992 Aug;17(4):315-25.
3	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
5	AIT-082 NeoTherapeutics Inc. IDrugs. 1998 Oct;1(6):694-9.
6	Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model.Neurobiol Aging.2013 Aug;34(8):2052-63.
7	Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019 Aug;62(8):1488-1500.
8	A new neuritogenetic compound BU-4514N produced by Microtetraspora sp. J Antibiot (Tokyo). 1993 Jun;46(6):875-83.
9	Phosphorylation of Extracellular Signal-Regulated Kinases (pERK1/2) in Bladder Afferent Pathways with Cyclophosphamide (CYP)-Induced Cystitis. Neuroscience. 2009 November 10; 163(4): 1353-1362.